Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients
Abstract Background Interstitial pneumonitis (IP) is a severe adverse event in patients receiving immunotherapy. Although PD-1/PD-L1 inhibitors and bevacizumab have been widely used in patients with non-small cell lung cancer (NSCLC), the interaction between their combination and IP is less known. M...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer
2025-10-01
|
| Seri Bilgileri: | Cancer Immunology, Immunotherapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s00262-025-04158-1 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|